19.12.2018 • NewsAir ProductsASUDede Willams

Air Products to Build Large-Scale ASU in Minnesota

Air Products to Build Large ASU in Minnesota (c) Air Products
Air Products to Build Large ASU in Minnesota (c) Air Products

US industrial gases producer Air Products plans to build, own and operate a new large-scale air separation unit (ASU) in the Twin Cities area (Minneapolis / St. Paul)  of Minnesota. The company said the new facility, scheduled to go on stream in early-to-mid-2020, will provide reliable liquid industrial gas options for customers and distributors in the region.

The plant will produce liquid nitrogen, oxygen and argon, allowing Air Products to strengthen and grow its presence in a dynamic geography, said Francesco Maione, the company’s vice president, Northern Region, Americas.

Malone said the investment shows the gases producer’s “further commitment” to customers in the US Midwest region and will expand its ability to reliably supply new customers as well.

By its own account, Air Products currently owns and operates more than 300 air separation plants in over 40 countries worldwide. In addition to its own plants, the company said it has sold, designed and built more than 2,000 air separation units for others globally.

Air Products’ cryogenic capabilities span plants with a capability of 50 t/d to single-train facilities with oxygen production capacities beyond 4,000 t/d, it said.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.